Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

In October 2024, the FDA determined that Eli Lilly’s tirzepatide injection shortage had been resolved. The U.S. pharma giant reported third-quarter revenue of $11.44 billion, up 20% year over ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Lilly’s tirzepatide medicines face strong competition ... pen and Rybelsus oral tablet for type II diabetes and as Wegovy injection for weight management. On Wednesday, Novo Nordisk reported ...